FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Hla patents



      
           
This page is updated frequently with new Hla-related patent applications. Subscribe to the Hla RSS feed to automatically get the update: related Hla RSS feeds. RSS updates for this page: Hla RSS RSS


Date/App# patent app List of recent Hla-related patents
09/18/14
20140275478
 Vaccines against chlamydia sp. patent thumbnailVaccines against chlamydia sp.
The present invention describes an efficient vaccine against a chlamydia trachomatis (ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various ct serovars.
09/18/14
20140274783
 Chlamydia-specific cd8+ t cells and methods of isolating patent thumbnailChlamydia-specific cd8+ t cells and methods of isolating
Isolated, chlamydia-specific, il-13 expressing cd8+ t cell clones are provided for understanding the biology of chlamydia infection and screening of therapeutics. Furthermore, methods are provided for isolating cd8+ t cells comprising the steps of infecting or identifying a naturally infected mammal with at least one species of chlamydia causing bacteria, allowing the bacteria to clear or for a t cell immune response to the natural infection, collecting immune splenocytes from the mammal, providing at least one antigen from a chlamydia-specific bacteria, and expanding and depleting the cd4+ t cell population or purifying the cd8 t cell population to isolate il-13 expressing cd8+ t cell clones..
09/11/14
20140256648
 Hjurp peptides and vaccines including the same patent thumbnailHjurp peptides and vaccines including the same
Isolated peptides derived from seq id no: 50 and fragments thereof that bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in cancer immunotherapy are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, provided they retain the requisite cytotoxic t cell inducibility of the original sequence.
08/28/14
20140242105
 Vaccines for chlamydia patent thumbnailVaccines for chlamydia
The present invention relates to means and methods to protect against disease caused by bacteria belonging to the genus chlamydia. In particular, the present invention relates to isolated b- and t-cell epitopes derived from the major outer membrane protein of chlamydia psittaci which can be used against an infection with a species of the genus chlamydia.
08/07/14
20140219995
 Inhibitors of bacterial type iii secretion system patent thumbnailInhibitors of bacterial type iii secretion system
Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type iii secretion systems are disclosed. The disclosed type iii secretion system inhibitor compounds are useful for combating infections by gram-negative bacteria such as salmonella spp., shigella flexneri, pseudomonas spp., yersinia spp., enteropathogenic and enteroinvasive escherichia coli, and chlamydia spp.
07/24/14
20140205656
 Modified cationic liposome adjuvants patent thumbnailModified cationic liposome adjuvants
The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the igg sub-type response and enhancing the cd8 response of the liposomal adjuvant. This technology can be used to increase the production of igg2 antibodies.
07/17/14
20140199336
 Tmem22 peptides and vaccines including the same patent thumbnailTmem22 peptides and vaccines including the same
Isolated peptides composed of the amino acid sequence of seq id no: 33 or fragments thereof that bind to hla antigens and have cytotoxic t lymphocyte (ctl) inducibility and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic t cell inducibility.
07/17/14
20140199335
 C1orf59 peptides and vaccines including the same patent thumbnailC1orf59 peptides and vaccines including the same
The present invention provides isolated peptides having the amino acid sequence of seq id no: 43 or immunologically active fragments thereof, which bind to hla antigen and have cytotoxic t lymphocyte (ctl) inducibility. The present invention further provides peptides which include one, two, or several amino acid insertions, substitution or addition to the aforementioned peptides or fragments, but still have the cytotoxic t cell inducibility.
06/26/14
20140178409
 Sema5b peptides and vaccines including the same patent thumbnailSema5b peptides and vaccines including the same
As discussed in detail herein, isolated epitope peptides derived from sema5b bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite hla binding and/or ctl inducibility of the original sequences.
06/05/14
20140154281
 Mphosph1 peptides and vaccines including the same patent thumbnailMphosph1 peptides and vaccines including the same
As discussed in greater detail herein, isolated epitope peptides derived from mphosph1 bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned mphosph1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite ctl inducibility of the original sequences.
05/22/14
20140142134
Inhibitors of bacterial type iii secretion system
Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type iii secretion systems are disclosed. The disclosed type iii secretion system inhibitor compounds are useful for combating infections by gram-negative bacteria such as salmonella spp., shigella flexneri, psendomonas spp., yersinia spp., en tero pathogenic and enteroinvasive escherichia coli, and chlamydia spp.
05/01/14
20140120536
Polynucleotides for the amplification and detection of chlamydia trachomatis and neisseria gonorrhoeae
Polynucleotides useful for detecting chlamydia trachomatis and/or neisseria gonorrhoeae in a test sample, kits, a nucleic acid amplification method and detection method including the same.. .
05/01/14
20140120129
Chlamydia antigens
Chlamydia antigens (e.g., polypeptides, polypeptide fragments, and fusion proteins) are provided. Also provided are vaccines and pharmaceutical compositions for treating or preventing a bacterial infection, such as chlamydia, in a subject..
05/01/14
20140120038
Nanoparticles for imaging and treating chlamydial infection
Compositions of nanoparticles and targeting moieties for imaging and treating chlamydial infection are provided, including nanoparticles conjugated to folic acid and comprising at least one antibiotic effective against chlamydia.. .
04/17/14
20140107357
Tigecycline crystalline hydrate and preparation method therefor and use thereof
Provided are a tigecycline crystalline hydrate, and a preparation method therefor and use thereof. The crystalline hydrate has high stability for storage, and is used for the manufacture of a medicament for treating or preventing the infection of respiratory system, hepatobiliary system, facial features, urogenital system, bone and joint, skin and soft tissue and endocarditis, septicemia, meningitis caused by susceptible strains of gram-positive or gram-negative bacteria, anaerobic bacteria, chlamydia, and mycoplasma in human or animal..
04/10/14
20140099733
Methods of detecting antibodies specific for denatured hla antigents
The invention is directed to methods of screening for hla antibodies comprising detecting antibodies specific for native hla antigens and denatured hla antigens. The invention also provides for methods of removing antibodies specific for denatured hla antigens or antibodies specific for native hla antigens from a serum sample.
04/03/14
20140093510
Chlamydia antigens
The invention provides chlamydia antigens for use in the treatment, prevention and/or diagnosis of chlamydia infection. In particular, the invention provides antigens ct733, ct1 53, ct601, ct279, ct443, ct372, ct456, ct381, ct255, ct341, ct716, ct745, ct387, ct812, ct869, ct166, ct175, ct163, ct214, ct721, ct127, ct043, ct823 and/or ct600 from c.
03/13/14
20140072569
Emp2 antibodies and their therapeutic uses
The present invention provides methods and compositions useful in the treatment or prevention of chlamydia infections and cancer. The methods and compositions inhibit the entry of chlamydia into a host cell expressing emp2 by interfering with the interaction between the chlamydia and emp2.
02/27/14
20140056967
Vaccines against chlamydial infection
The present invention relates to compositions comprising proteins or polynucleotides of chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of chlamydia infection.. .
01/23/14
20140023671
Tomm34 peptides and vaccines including the same
The present invention provides isolated peptides or the fragments derived from seq id no: 42, which bind to an hla antigen and induce cytotoxic t lymphocytes (ctl). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences.
01/16/14
20140017689
Method for detecting nucleic acids
Method for detecting nucleic acids which employs a double-stranded oligonucleotide probe containing i) a first probe including a first label moiety, and ii) a second probe partially complementary with the first probe and including a second label moiety capable of interacting with the first moiety when brought in close proximity with each other, the second moiety being a quencher or acceptor of emission of the first moiety. The first or second probe includes a sequence complementary to that of a target nucleotide, and the second or first probe, respectively, includes a sequence complementary to a complement of the target nucleotide sequence of the nucleic acid to be detected.
12/26/13
20130345277
Modulators of gtpase and use in relevant treatment
The present invention relates to molecules which function as selective modulators of the ras-homologous (rho) family of small gtpases, in particular, cdc42 gtpase and their use to treat diseases, for example cancers, including metastatic cancer, genetic and acquired diseases where activation of cdc42 gtpase plays a pivotal role, such as neurodegenerative diseases, rheumatoid arthritis, atherosclerosis, diabetes type i, autosomal polycystic kidney disease, cystic kidney disease, precystic kidney disease, microbial infections, including chlamydia infections, e. Coli infections, h.
12/26/13
20130344109
Immunogenic compositions
The present invention provides compositions comprising a chlamydial major outer membrane protein (referenced herein as “momp”), from at least one chlamydial serovar and an adjuvant, characterized in that the adjuvant comprises the product e6020 having cas number 287180-63-6. The composition may further comprise at least one carrier system (e.g., emulsion, mineral particle).
12/26/13
20130344078
Emp2 antibodies and their therapeutic uses
The present invention provides methods and compositions useful in the treatment or prevention of chlamydia infections and cancer. The methods and compositions inhibit the entry of chlamydia into a host cell expressing emp2 by interfering with the interaction between the chlamydia and emp2.
11/21/13
20130309259
Wdhd1 peptides and vaccines including the same
Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides or immunogenic fragments derived from seq id no: 32, that bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) are provided.
11/14/13
20130302442
Methods of using (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide
A method of treating a bacterial infection, e.g., a bacterial infection with methicillin resistant staphylococcus aureus, helicobacter pylori, chlamydia trachomatis, or chlamydia pneumonia, comprising administering to a subject (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide or a pharmaceutically acceptable salt thereof is disclosed. More specifically, a method of treating a bacterial infection comprising administering to a subject crystalline mono hydrochloride salt, crystalline mono mesylate salt or crystalline mono sulfate salt of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide is disclosed..
10/31/13
20130288238
Methods and compositions for detecting serotypes of chlamydia trachomatis capable of causing lymphogranuloma venereum
Disclosed are methods and compositions for conducting assays utilizing real-time polymerase chain reactions (“pcrs”) in detection of serotypes l i, l ii, and l iii, but not stereotype b, of chlamydia trachomatis, capable of causing lymphogranuloma venereum (“lgv”). These assays take advantage of a deletion occurring in the cytotoxin gene locus specific to the l i, l ii, and l iii serotypes.
10/31/13
20130287805
C18orf54 peptides and vaccines including the same
Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides or immunogenic fragments derived from seq id no: 35, that bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) are provided.
10/17/13
20130276154
Bank of stem cells for producing cells for transplantation having hla antigens matching those of transplant recipients, and methods for making and using such a stem cell bank
Methods for producing stem cell banks, preferably human, which optionally may be transgenic, e.g., comprised of homozygous mhc allele cell lines are provided. These cells are produced preferably from parthenogenic, ivf, or same-species or cross-species nuclear transfer embryos or by dedifferentiation of somatic cells by cytoplasm transfer.
10/17/13
20130274122
Assay for chlamydia trachomatis by amplification and detection of chlamydia trachomatis pmpa gene
A region of the chlamydia trachomatis pmpa gene has been identified which is useful for performing amplification assays to determine specifically whether c. Trachomatis is present in the sample being tested.
09/26/13
20130251749
Methods and compositions for chlamydial antigens as reagents/strategies for diagnosis and treatment of chlamydial infection and disease
The present invention provides chlamydia proteins and methods of use in diagnostic and detection assays as well as in treatment and immunization protocols.. .
09/05/13
20130230527
Emp2 antibodies and their therapeutic uses
The present invention provides methods and compositions useful in the treatment or prevention of chlamydia infections and cancer. The methods and compositions inhibit the entry of chlamydia into a host cell expressing emp2 by interfering with the interaction between the chlamydia and emp2.
08/15/13
20130209998
Microbial assay
A method of detecting genetic material deriving from chlamydia trachomatis comprising detection of a specified nucleic acid sequence, optionally using specific primers and probes and optionally in combination with the detection of genetic material deriving from pectobacterium atrosepticum as an internal control; and related products and kits.. .
08/01/13
20130195907
Omv vaccines
The invention is in the field of outer membrane vesicles (omv) and their uses. More particularly the present invention provides omv obtained from a bacterium being an ompa mutant and/or a mutant in one or more components of the tolpal complex and presenting a heterologous antigen on its surface.
07/04/13
20130171238
Immunogenic compositions for chlamydia trachomatis
The invention relates to immunogenic compositions comprising combinations of chlamydia trachomatis antigens and their use in vaccines. The composition may comprise at least two components, one component of which comprises chlamydia trachomatis antigens for eliciting a chlamydia trachomatis specific th1 immune response and another component of which comprises antigens for eliciting a chlamydia trachomatis specific th2 immune response.
06/20/13
20130156805
Chimeric momp antigen
The present invention regards polypeptides capable of eliciting an immunological response that is protective against chlamydia trachomatis. The polypeptide comprises a first amino acid sequence which has at least 90% homology with the amino acid sequence according to seq id no: 1 and a second amino acid sequence which has at least 90% homology with the amino acid sequence according to seq id no: 2.
06/20/13
20130156804
Porin b (porb) as a therapeutic target for prevention and treatment of infection by chlamydia
The present invention features peptides of a porb polypeptide, which porb peptides are useful in production of antibodies that bind the full-length porb polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more porb peptides (other than a full-length porb polypeptide), which peptides contain at least one epitope that can elicit chlamydia-neutralizing antibodies.
06/20/13
20130156775
Chlamydia trachomatis antigens
Proteins encoded by chlamydia trachomatis which are immunogenic in humans as a consequence of infection have been identified using western blots of two-dimensional electrophoretic maps. Several known immunogens were identified, as were proteins not previously known to be immunogens, and proteins not previously reported as expressed gene products..
06/06/13
20130143757
Methods and compositions for chlamydial antigens as reagents for diagnosis of tubal factor infertility and chlamydial infection
The present invention provides chlamydia proteins and fragments thereof and methods of use in diagnostic assays.. .
06/06/13
20130143252
Method for detection of inflammation in the urinary tract or urethra
A method for detecting inflammation in the urinary tract or urethra of a patient, especially urethritis, comprises a) contacting leucocytes obtained from a urine sample provided by the patient with a luminescence reagent which emits light on reaction with an oxidant; b) adding an activator to the mixture of leucocytes and luminescence reagent; c) continuously monitoring and/or measuring light emitted by the luminescence reagent over a predetermined time period commencing before and ending after the addition of the activator. The light emission is indicative of the presence or absence of inflammation in the urinary tract or urethra of the patient.
05/09/13
20130116302
Pharmaceutical composition for the treatment of chlamydial infection
Subject of the present invention is a pharmaceutical composition comprising at least one inhibitor of a microorganism selected from the family chlamydiaceae.. .
05/02/13
20130108664
Cdca5 peptides and vaccines including the same
Isolated peptides derived from seq id no: 21 and fragments thereof that bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite hla binding and/or ctl inducibility of the original sequences.
04/18/13
20130095505
Detection of lipid oxidising abzymes in samples
This invention relates to the finding that lipid oxidising abzymes damage chlamydia antigens in a sample and the extent of damage provides a measure of the level or activity of the abzymes in the sample. Lipid oxidising abzymes may be measured or detected, for example, by abrogating or abolishing abzyme mediated lipid oxidation activity in a sample, and determining the binding of antibodies in the sample to a chlamydia antigen relative to controls.
04/18/13
20130095487
Interferon-gamma response as a diagnostic test for persistent chlamydial infections
The present invention provides a non-invasive, sensitive, and convenient diagnostic test for persistent chlamydial infection and diseases arising from persistent chlamydial infection. The present invention also provides kits for diagnosis of persistent chlamydial infection..
04/18/13
20130095128
Ect2 peptides and vaccines including the same
Isolated peptides derived from seq id no: 42 and fragments thereof that bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore-mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite hla binding and/or ctl inducibility of the original sequences.
04/18/13
20130095080
Compositions and methods for providing hematopoietic function
The present invention relates to methods and compositions for providing hematopoietic function to human patients in need thereof, by selecting a pool of expanded human cord blood stem/progenitor cell samples for administration to the patient, wherein the samples in the pool collectively do not mismatch the patient at more than 2 of the hla antigens or alleles typed in the patient; and administering the selected pool of expanded human cord blood stem/progenitor cell samples to the patient. Methods for obtaining the pools of expanded human cord blood stem/pro-genitor cell samples, banks of frozen pools of expanded human umbilical cord blood stem/progenitor cell samples, and methods for producing such banks are also provided herein..
03/14/13
20130064840
Hjurp peptides and vaccines including the same
Isolated peptides derived from seq id no: 50 and fragments thereof that bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic t cell inducibility of the original sequence.
03/07/13
20130059306
Primer and probe for detecting chlamydia trachomatis, and method for detecting chlamydia trachomatis using same
The present invention relates to an oligonucleotide which is designed on the basis of a nucleotide sequence shown in seq id no: 1 or seq id no: 2 and hybridizes with the endogenous plasmid gene of chlamydia trachomatis, oligonucleotide primer and probe for detecting chlamydia trachomatis, the detection method of chlamydia trachomatis using said primer and probe, and a primer for detecting chlamydia trachomatis of said oligonucleotide or the use to a probe design.. .
02/28/13
20130053336
Treatment of chlamydiaceae infections by means of beta-lactams
The invention relates to a method for treating infections of bacteria of the chlamydiaceae family using a β-lactam. The invention also relates to a method for treating diseases caused by an infection of bacteria of the chlamydiaceae family using a β-lactam..
02/21/13
20130047274
Cd4 t-cells involved in mammalian host response to epithelial cell infections and uses thereof
Mhc class ii-restricted chlamydia-specific cd4 t cell clones recognize infected upper reproductive tract epithelial cells as early as 12 hours post infection. The timing and degree of t cell activation are dependent on the interferon milieu.


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Hla for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Hla with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



1.6853

3488

5 - 0 - 72